Suppr超能文献

当今哮喘治疗的进展:MART和易纳器的作用

Today's improvement in asthma treatment: role of MART and Easyhaler.

作者信息

Di Marco Fabiano

机构信息

Department of Health Sciences, University of Milan; Head Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy.

出版信息

Multidiscip Respir Med. 2020 Aug 5;15(1):649. doi: 10.4081/mrm.2020.649. eCollection 2020 Jan 28.

Abstract

Asthma affects more than 330 million people worldwide, but many analyses have shown that there are still a lot of unmet needs for both patients and physicians in the treatment of asthma: poor adherence to treatment is one of the main causes of sub-optimal clinical results. Maintenance and Reliever Therapy (MART) with the combination of formoterol and inhaled corticosteroids (ICS) has an established scientific rationale and demonstrated to reduce asthma exacerbations. The aim of this review is to highlight how in asthmatic patients MART can be able to express its maximum therapeutic potential when administered through an 'ideal inhaler'. Since the treatment may be necessary several times a day, the use of a single combination inhaler simplifies the management, potentially improving adherence; moreover, easiness of use and comfort in administration of asthma treatment devices are not secondary aspects. Asthmatic patients are often young, with a normal relational and working life and they could request for a comfortable and not too noticeable device. Finally to the "ideal inhaler" is requested to guarantee accuracy, dose consistency, and resistance to stress conditions. Easyhaler® more closely demonstrates many expected characteristics: effective, consistent performance regardless of inspiration rate, stability, versatility, with several patient acceptability advantages. Asthma control is enhanced by a strong adherence obtained through the combination in a single inhaler of both maintenance and reliever therapy and the availability of a device as close as possible to the characteristics of the ideal inhaler.

摘要

哮喘影响着全球超过3.3亿人,但许多分析表明,在哮喘治疗方面,患者和医生仍有许多未满足的需求:治疗依从性差是临床效果欠佳的主要原因之一。福莫特罗与吸入性糖皮质激素(ICS)联合的维持和缓解治疗(MART)有既定的科学依据,并已证明可减少哮喘发作。本综述的目的是强调在哮喘患者中,当通过“理想吸入器”给药时,MART如何能够发挥其最大治疗潜力。由于治疗可能一天需要进行数次,使用单一的联合吸入器可简化管理,有可能提高依从性;此外,哮喘治疗设备的易用性和使用舒适度也并非次要方面。哮喘患者通常较为年轻,有着正常的社交和工作生活,他们可能会要求使用一种舒适且不太引人注目的设备。最后,“理想吸入器”需要保证准确性、剂量一致性以及对压力条件的耐受性。易纳器®更符合许多预期特性:有效,无论吸气速率如何都能保持一致性能,稳定性好,通用性强,具有多项患者可接受性优势。通过在单一吸入器中联合维持和缓解治疗,并提供一款尽可能接近理想吸入器特性的设备,可实现较高的依从性,从而增强哮喘控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abcc/7460660/1be65031121e/mrm-15-1-649-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验